Core Viewpoint - Concord Medical Services Holdings Limited has received a notification from the New York Stock Exchange indicating that it is below compliance standards due to the trading price of its American depositary shares, with a cure period until August 12, 2024, to regain compliance [1][2]. Company Overview - Concord Medical is a healthcare provider in China specializing in cancer treatment, research, education, and prevention, offering a full cycle of premium oncology services [4]. - The company aims to enhance the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics, as well as partnerships with other hospitals across China [4]. Compliance Details - The NYSE considers a company "below criteria" if the average closing price of its securities is less than 1.00 within the cure period [2]. - The company can regain compliance at any time during the cure period if it meets the required closing price on the last trading day of any calendar month [2]. Company Actions - In response to the compliance issue, the company intends to monitor market conditions and is considering its options to address the situation [3].
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price